Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce global or clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with SASP (moderate certainty).
1 finding from 1 review
Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in failure to induce global or clinical improvement compared with SASP (high certainty).
1 finding from 1 review
DMFT/DMFS index (dental caries experience) · Children aged 0-12 years in the United Kingdom
In UK studies, OHPPs were associated with lower DMFT/S (OR 0.04, 95% CI 0.00 to 0.58; ungraded).
1 finding from 1 review
DMFT/DMFS index (dental caries experience) · Children aged 0-12 years in Ireland
The single Irish study showed lower DMFT/S with OHPP (OR 0.52, 95% CI 0.45 to 0.61; ungraded, single study).
1 finding from 1 review